Lanzatech Global, Inc. · NASDAQ:LNZA
Lanzatech Global — Merger or Acquisition (January 2025)
10 slides from Lanzatech Global's merger presentation, Jan 22, 2025
Slide 1: Accelerating the path to scale and commercialization of synthetic biology strains: LanzaX
Accelerating the path to scale and commercialization of globally sought-after synthetic biology strains LanzaX Nasdaq: LNZA Dedicated Strain Innovation +
Slide 2: Forward-looking statements
This presentation includes forward-looking statements regarding, among other things, the plans, strategies, and prospects, both business and financial, of LanzaTech. These statements are based on the beliefs, assumptions, projections and conclusions of LanzaTech’s management. Forward-looking stateme
Slide 3: A Commercial Launchpad for Sustainable Chemical Production
3 and other shareholders 50 % Tharsis Capital and other shareholders to contribute cash sufficient for the joint venture to reach profitability; Tharsis Capital brings deep experience in chemicals and sustainable technology sectors and will be a valued collaborative partner LanzaTech contributes lic
Slide 4: Symbiotic Relationship with LanzaTech
LanzaX is designed to take the reins on existing and future research and development projects, enabling LanzaTech to focus on high-impact commercial growth priorities of its core biorefining platform, including increasing opportunities in sustainable aviation fuel production (SAF) 4 Symbiotic Relati
Slide 5: Compelling Total Addressable Market Spanning Multiple Verticals
5 Compelling Total Addressable Market Spanning Multiple VerticalsLanzaX P ro d u ct V al u e Market Size $200M $50B $500/MT $5,000/MT Packaging Rubber Solvents Fragrances Specialty Chemicals LanzaX has the potential to be a transformational biomanufacturing platform that leverages dedicated capital
Slide 6: Revenue Model – Driving Profitable Growth
Value proposition: Value creation from product sales while reducing emissions LanzaX *JDA- Joint Development Agreements Revenue Model – Driving Profitable Growth Delivers Research and New Microbes Unique Strain Innovation $ $ CUSTOMERS Global brands, Government Agencies, and Universities LanzaX JDA*
Slide 7: Competitive Edge: Uniquely Positioned Over Competitors
7 Competitive EdgeLanzaX Uniquely Positioned Over Competitors Most advanced synthetic biology platform for C1 microbes and partnership with LanzaTech provides powerful path to scale Capabilities: Service Model Organism Portfolio Biofoundry Gas Handling Scale Up C1 Microbes Sugar Microbes FungiYes Ye
Slide 8: Capabilities
8 CapabilitiesLanzaX ✓ Leading synthetic biology platform for C1 microbes ✓ State-of-the art strain modeling, AI, and synthetic biology capabilities across full design-build-test-learn cycle ✓ Building on 15+ years of genetic tool development and optimization of continuous, gas fermentation organism
Slide 9: Team
9 TeamLanzaX Projected annual cost reduction of ~$8 million to LanzaTech, primarily driven by employee transfer to LanzaX CEO Strain Design & Modeling Strain Validation & Fermentation Commercialization & Business Development Science & Innovation Advisors Support Functions ▪ LanzaTech to transfer ove
Slide 10: Investor contact
Investor contact: Kate Walsh VP Investor Relations Kate.Walsh@lanzatech.com
LanzaTech Global — Merger or Acquisition (January 2025) on 6ix